HTFL — HeartFlow, Inc. Stock Price, Chart & AI Report

Neutral Dec 28, 2025 • 06:08 UTC The Motley Fool • Robert Izquierdo

Is Recent IPO Stock Heartflow a Buy After a Director Scooped Up Shares Worth Over $1 Million?

HeartFlow director Jeffrey Lightcap purchased 40,000 shares worth $1.05 million on December 16, 2025, just after the stock hit a 52-week low of $25.38. While the company shows strong revenue growth of 41% year-over-year in Q3, it faces significant profitability challenges with net losses expanding to $50.9 million. The insider buy suggests confidence in the company's future, but the stock remains risky for investors given its recent IPO status and limited public company track record.

HTFL insider buying IPO cardiac diagnostics AI-driven diagnostics revenue growth net losses director purchase

Sentiment note

Mixed signals: positive insider buying and strong 41% YoY revenue growth suggest confidence, but significant net losses ($50.9M in Q3) and recent IPO status with limited track record create substantial risk. The article concludes it's only suitable for high-risk tolerance investors, indicating cautious optimism rather than a clear buy recommendation.

Positive Nov 9, 2025 • 18:30 UTC GlobeNewswire Inc. • Timothy Fairbairn, Ph.D.

AHA 2025: Late-Breaking Data Reinforce the Prognostic Power of AI-Driven Heartflow Plaque Analysis as the Most Clinically Validated Framework for Coronary Risk Stratification

Heartflow presented late-breaking data at AHA 2025 demonstrating that total plaque volume can predict cardiovascular events with high accuracy, showing patients in the highest plaque volume stage have over 5x greater risk of major cardiovascular events.

HTFL AI coronary artery disease plaque analysis cardiovascular risk medical technology

Sentiment note

Company presented groundbreaking research showing significant predictive power of their AI-driven plaque analysis technology, with potential to improve cardiovascular disease management and patient outcomes